Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Posted: September 25, 2022 at 2:04 am

Carlsbad, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it had made equity grants to two new employees under its 2021 Inducement Plan.

Read more:
Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Related Posts